PDCL2

Across TCGA pan-cancer cohorts, PDCL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDCL2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PDCL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCL2 expression acts as an unfavorable survival marker.

THYM, SCLC, and COAD are the cancer types where PDCL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	7	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDCL2–THYM (OS)

Open the THYM breakdown →